Phase 2a randomised trial of 72 patients with asthma: inhaled elarekibep was well tolerated over 4 weeks; in 22 with uncontrolled asthma, 3 mg raised FEV1 by 196 mL vs placebo. Development was stopped after lung findings in a primate toxicology study.
RCTn = 72
Hugo et al. Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)